Primary prevention of venous thromboembolism for cancer patients in randomized controlled trials : a bibliographical analysis of funding and trial characteristics
© 2024 The Author(s)..
Background: The majority of randomized controlled trials (RCTs) investigating venous thromboembolism (VTE) prophylaxis in patients with cancer involve commercial sponsorship. Commercial sponsorship overcomes feasibility limitations inherent in RCTs, such as recruitment and funding, but has attracted scrutiny for its potential for bias.
Objectives: In RCTs of VTE prophylaxis in patients with cancer, how do trial characteristics compare between commercially sponsored RCTs and noncommercially sponsored RCTs?.
Methods: Medline, Embase, and Cochrane Central Register of Controlled Trials were searched for RCTs that investigated at least 1 pharmacologic intervention for VTE prophylaxis in adult patients with cancer. Screening and data extraction were conducted by independent reviewers. Outcomes included trial characteristics, reporting of favorable outcomes, protocol-manuscript discrepancies, and appraisal of spin. Outcomes were compared using the independent t-test, Mann-Whitney U-test, Pearson chi-squared test, and Fisher's exact test. Logistic regression was performed to identify factors associated with possible bias.
Results: Of the 54 trials analyzed, 34 (63%) reported commercial sponsorship. Commercial sponsorship was not associated with the reporting of favorable outcomes, presence of spin, retrospective registration, or protocol-manuscript discrepancy. Spin was most prevalent in the abstract conclusions (9 out of 17 [53.3%]) and manuscript conclusions (8 out of 17 [46.7%]).Commercially sponsored trials had a higher rate of intention-to-treat analysis. Noncommercially sponsored trials were more likely to report retrospective registration of trial protocol and the use of composite primary outcomes.
Conclusion: There were few significant differences between trial characteristics, suggesting that the evidence from commercially sponsored trials investigating VTE prophylaxis in patients with cancer is unlikely to be subject to bias attributable to commercial sponsorship.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Research and practice in thrombosis and haemostasis - 8(2024), 1 vom: 29. Jan., Seite 102315 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Lucy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bias∗ |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.rpth.2024.102315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368949184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368949184 | ||
| 003 | DE-627 | ||
| 005 | 20240229164940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rpth.2024.102315 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368949184 | ||
| 035 | |a (NLM)38404943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Lucy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary prevention of venous thromboembolism for cancer patients in randomized controlled trials |b a bibliographical analysis of funding and trial characteristics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Background: The majority of randomized controlled trials (RCTs) investigating venous thromboembolism (VTE) prophylaxis in patients with cancer involve commercial sponsorship. Commercial sponsorship overcomes feasibility limitations inherent in RCTs, such as recruitment and funding, but has attracted scrutiny for its potential for bias | ||
| 520 | |a Objectives: In RCTs of VTE prophylaxis in patients with cancer, how do trial characteristics compare between commercially sponsored RCTs and noncommercially sponsored RCTs? | ||
| 520 | |a Methods: Medline, Embase, and Cochrane Central Register of Controlled Trials were searched for RCTs that investigated at least 1 pharmacologic intervention for VTE prophylaxis in adult patients with cancer. Screening and data extraction were conducted by independent reviewers. Outcomes included trial characteristics, reporting of favorable outcomes, protocol-manuscript discrepancies, and appraisal of spin. Outcomes were compared using the independent t-test, Mann-Whitney U-test, Pearson chi-squared test, and Fisher's exact test. Logistic regression was performed to identify factors associated with possible bias | ||
| 520 | |a Results: Of the 54 trials analyzed, 34 (63%) reported commercial sponsorship. Commercial sponsorship was not associated with the reporting of favorable outcomes, presence of spin, retrospective registration, or protocol-manuscript discrepancy. Spin was most prevalent in the abstract conclusions (9 out of 17 [53.3%]) and manuscript conclusions (8 out of 17 [46.7%]).Commercially sponsored trials had a higher rate of intention-to-treat analysis. Noncommercially sponsored trials were more likely to report retrospective registration of trial protocol and the use of composite primary outcomes | ||
| 520 | |a Conclusion: There were few significant differences between trial characteristics, suggesting that the evidence from commercially sponsored trials investigating VTE prophylaxis in patients with cancer is unlikely to be subject to bias attributable to commercial sponsorship | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a VTE prophylaxis | |
| 650 | 4 | |a bias∗ | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a funding source | |
| 650 | 4 | |a neoplasms∗ | |
| 650 | 4 | |a primary prevention∗ | |
| 650 | 4 | |a randomized controlled trials∗ | |
| 650 | 4 | |a sponsorship | |
| 650 | 4 | |a trial characteristics | |
| 650 | 4 | |a venous thromboembolism∗ | |
| 700 | 1 | |a Kherani, Jayhan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pei Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Horta, Angelina |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Allen |e verfasserin |4 aut | |
| 700 | 1 | |a Eshaghpour, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Crowther, Mark Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research and practice in thrombosis and haemostasis |d 2017 |g 8(2024), 1 vom: 29. Jan., Seite 102315 |w (DE-627)NLM277257743 |x 2475-0379 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:102315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rpth.2024.102315 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 29 |c 01 |h 102315 | ||